These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 8824563

  • 1. Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.
    Devys A, Thedrez P, Gautherot E, Faivre-Chauvet A, Saï-Maurel C, Rouvier E, Auget JL, Barbet J, Chatal JF.
    Int J Cancer; 1996 Sep 17; 67(6):883-91. PubMed ID: 8824563
    [Abstract] [Full Text] [Related]

  • 2. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Fiche M, Gautherot E, Barbet J, Chatal JF.
    J Nucl Med; 1998 Sep 17; 39(9):1608-13. PubMed ID: 9744353
    [Abstract] [Full Text] [Related]

  • 3. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F, Faibre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, Le Boterff J, Barbet J, Chatal JF, Thédrez P.
    J Nucl Med; 1999 Jan 17; 40(1):198-204. PubMed ID: 9935077
    [Abstract] [Full Text] [Related]

  • 4. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Campion L, Fiche M, Gautherot E, Le Boterff J, Barbet J, Chatal JF, Thédrez P.
    Clin Cancer Res; 1999 Oct 17; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [Abstract] [Full Text] [Related]

  • 5. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM.
    Bioconjug Chem; 2002 Oct 17; 13(5):1054-70. PubMed ID: 12236788
    [Abstract] [Full Text] [Related]

  • 6. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, Goldenberg DM, Corstens FH, Boerman OC.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [Abstract] [Full Text] [Related]

  • 7. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids.
    Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach JP.
    Cancer Res; 1987 Mar 15; 47(6):1627-33. PubMed ID: 3545451
    [Abstract] [Full Text] [Related]

  • 8. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten.
    Gautherot E, Bouhou J, Le Doussal JM, Manetti C, Martin M, Rouvier E, Barbet J.
    Cancer; 1997 Dec 15; 80(12 Suppl):2618-23. PubMed ID: 9406716
    [Abstract] [Full Text] [Related]

  • 9. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
    Gestin JF, Loussouarn A, Bardiès M, Gautherot E, Gruaz-Guyon A, Saï-Maurel C, Barbet J, Curtet C, Chatal JF, Faivre-Chauvet A.
    J Nucl Med; 2001 Jan 15; 42(1):146-53. PubMed ID: 11197965
    [Abstract] [Full Text] [Related]

  • 10. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
    Gautherot E, Kraeber-Bodéré F, Daniel L, Fiche M, Rouvier E, Saï-Maurel C, Thedrez P, Chatal JF, Barbet J.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
    [Abstract] [Full Text] [Related]

  • 11. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
    Robert B, Mach JP, Mani JC, Ychou M, Folli S, Artus JC, Pèlegrin A.
    Cancer Res; 1996 Oct 15; 56(20):4758-65. PubMed ID: 8840995
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
    Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardiès M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
    [Abstract] [Full Text] [Related]

  • 13. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, Barbet J.
    J Nucl Med; 1998 Nov 01; 39(11):1937-43. PubMed ID: 9829586
    [Abstract] [Full Text] [Related]

  • 14. A universal pretargeting system for cancer detection and therapy using bispecific antibody.
    Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, Goldenberg DM.
    Cancer Res; 2003 Jan 15; 63(2):354-63. PubMed ID: 12543788
    [Abstract] [Full Text] [Related]

  • 15. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
    Mirallié E, Saï-Maurel C, Faivre-Chauvet A, Regenet N, Chang CH, Goldenberg DM, Chatal JF, Barbet J, Thedrez P.
    Eur J Nucl Med Mol Imaging; 2005 Aug 15; 32(8):901-9. PubMed ID: 15864584
    [Abstract] [Full Text] [Related]

  • 16. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, Martin M, Le Doussal JM, Barbet J.
    J Nucl Med; 2000 Mar 15; 41(3):480-7. PubMed ID: 10716323
    [Abstract] [Full Text] [Related]

  • 17. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids.
    Langmuir VK, Mendonca HL, Woo DV.
    Cancer Res; 1992 Sep 01; 52(17):4728-34. PubMed ID: 1511438
    [Abstract] [Full Text] [Related]

  • 18. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
    Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, Wieland E, Nebendahl K, Schmidberger H, Goldenberg DM, Becker W.
    Int J Cancer; 1998 Aug 31; 77(5):787-95. PubMed ID: 9688314
    [Abstract] [Full Text] [Related]

  • 19. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
    Karacay H, McBride WJ, Griffiths GL, Sharkey RM, Barbet J, Hansen HJ, Goldenberg DM.
    Bioconjug Chem; 2000 Aug 31; 11(6):842-54. PubMed ID: 11087333
    [Abstract] [Full Text] [Related]

  • 20. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J.
    J Nucl Med; 2006 Feb 31; 47(2):247-55. PubMed ID: 16455630
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.